Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?

Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?

Moderna stock rallied by close to 20% in Tuesday’s trading, after it announced positive results from mid-stage trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck.